Pneumococcal Conjugate Vaccine not checked
Sanofi · PCV21 vaccine · PCV21
FollowEvery change as it happens, and a Monday email
Trials
7 active
11 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular”In the company’s words, NCT06736041 on ClinicalTrials.gov
- Tested for
- Pneumococcal Immunization (5 trials), Pneumococcal Infections, Sickle Cell Disease
- Main trialPhase 3
- “The purpose of this study is to evaluate the safety and immunogenicity of PCV21 versus 20vPCV ( 20-valent pneumococcal conjugate vaccine, Prevnar 20) for catch-up vaccination in infants (7 to 11 MoA-Months of age), toddlers (12 to 23 MoA), and children/adolescents (2 to 5 YoA and 6 to 17 YoA-years of age).”In the company’s words, NCT06838000 on ClinicalTrials.gov
- Other names
- PCV21 vaccine · Pneumococcal Conjugated Vaccine · PCV21 · 515 · SP0202-IIb · SP0202-VI · SP0202-VII
Other drugs for Pneumococcal Immunization
- 13-Valent Pneumococcal Polysaccharide Conjugate VaccineCanSino Biologics Inc. · Phase 3
- PG4Pfizer · Phase 3
- Pneumococcal conjugate vaccinePfizer · Phase 3
- PrevnarPfizer · Phase 3
- Prevention of pneumococcal disease from 24 serotypesReinovax Biologics Co., LTD · Phase 3
- 13-valent pneumococcal conjugate vaccinePfizer · Phase 3
Coming up7
- 1 DecPhase 3 trial completes · ClinicalTrials.gov
- 7 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- 17 May 2027Phase 3 trial completes · ClinicalTrials.gov
- 7 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- 25 Aug 2027Phase 3 trial completes · ClinicalTrials.gov
- 10 Sep 2027Phase 3 trial completes · ClinicalTrials.gov
- 22 Oct 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 1 Dec 2026 | Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents | |
| Phase 3Recruiting | 7 Jan 2027 | Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease | |
| Phase 3Active, not recruiting | 17 May 2027 | Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age | |
| Phase 3Recruiting | 7 Jun 2027 | Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age | |
| Phase 3Active, not recruiting | 25 Aug 2027 | Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age | |
| Phase 3Active, not recruiting | 10 Sep 2027 | Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age | |
| Phase 3Active, not recruiting | 22 Oct 2027 | Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age | |
| Phase 3Completed | Sep 2013 | Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers | |
| Phase 2Completed | 9 Aug 2021 | Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years. | |
| Phase 2Completed | 10 Aug 2023 | Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants | |
| Phase 1Completed | 30 Sep 2019 | Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026